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Aspirin is the most widely prescribed agent to reduce the platelet-mediated contributions to
atherosclerosis, coronary thrombosis and restenosis after angioplasty. While aspirin treatment
has led to significant reductions in morbidity and mortality in many clinical trials, there are
several scenarios in which aspirin may fail to provide a full antithrombotic benefit. The cyclic
flow model of experimental coronary thrombosis suggests that elevations of plasma cat-
echolamines, high shear forces acting on the platelets in the stenosed lumen and the presence
of multiple, input stimuli can activate platelets through different mechanisms that may lead
to thrombosis despite aspirin therapy.
Aspirin therapy is limited because it only blocks some of the input stimuli, leaving
aspirin-independent pathways through which coronary thrombosis can be precipitated. These
include thrombin and thrombogenic arterial wall substrates such as tissue factor. New agents
that block the adenosine diphosphate (ADP) receptor, or regulate platelet free cytosolic
calcium, such as direct nitric oxide donors, may be more potent overall than aspirin. Agents
that block the platelet integrin GPIIb-IIIa receptor inhibit the binding of fibrinogen to
platelets regardless of which input stimuli activate the platelet and, thus, as demonstrated in
the cyclic flow model, would be much more potent than aspirin as an antithrombotic agent.
The cyclic flow model has been useful in predicting which agents are likely to be of benefit
in clinical trials. (J Am Coll Cardiol 1999;33:295–303) © 1999 by the American College of
Cardiology
Platelet interactions with damaged arterial walls are known to
contribute to the development of thrombosis, atherosclerosis
and restenosis after angioplasty, atherectomy or arterial stent-
ing. Ruptured atherosclerotic plaques with platelet-mediated
occlusive thrombosis are known to lead to acute coronary
syndromes and ischemic stroke. Thus, for over 30 years, there
has been an intense search for effective platelet inhibitors.
HISTORICAL BACKGROUND
In the 1950s and 1960s, it was thought that patients with
coronary artery disease died from fibrin-mediated “coronary
thrombosis;” however, this was widely debated (1), with
some investigators suggesting that thrombosis occurred
after the fatal myocardial infarction rather than causing it
(2,3). Though platelet aggregates were sometimes observed
in postmortem thrombi, the specific role of platelets was
uncertain at that time.
The studies of Zucker and Weiss et al. in 1968 first showed
that aspirin inhibits platelet aggregation in vitro (4,5). Vane
demonstrated in 1971 that aspirin blocks the production of
prostaglandin synthesis in cells (6), and Smith and Willis
observed in the same year that aspirin inhibits platelet aggre-
gation by blocking prostaglandin production in vitro (7,8). In
1971, a trial of daily aspirin was started in 1,239 men who had
already had one myocardial infarction, with the hope of
preventing a second one. The results reported in 1974 were
inconclusive, although they reported a favorable trend (8). The
authors concluded that “further trials are urgently required to
establish whether or not this aspirin effect is real” (8). Similar
trials were begun at the same time.
DEVELOPMENT OF THE CYCLIC FLOW MODEL
In 1972, one of us (J.D.F.) developed a canine model of
coronary artery stenosis with intimal damage to mimic a
patient with coronary artery disease (PHD thesis, University
of Wisconsin, 1972). In this model the circumflex coronary
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artery of anesthetized dogs was dissected out and an
electromagnetic flowmeter probe was placed on the artery to
continuously measure coronary blood flow. A plastic encir-
cling cylinder was then placed around the outside of the
coronary artery distal to the flow probe. The cylinder
produced a 70% stenosis and intimal damage. The coronary
blood flow was shown to periodically decline to zero,
producing transient myocardial ischemia. The flow would
then suddenly spontaneously return to normal and the
ischemia would be resolved. It was subsequently shown that
the flow decline was caused by a platelet-mediated throm-
bus, gradually forming in the narrowed lumen, which cut off
the blood flow. When the friable, loosely packed thrombus
broke up and embolized distally, the blood flow was
suddenly restored. This model thus demonstrated “in vivo”
that periodic, acute platelet-mediated thrombotic occlusion,
followed by embolization, could occur in stenosed and
intimally damaged canine coronary arteries producing cyclic
reductions in coronary blood flow. In addition, the throm-
bus was produced by platelet interaction with damaged
arterial walls, and histologically consisted of mainly plate-
lets: some red cells but little fibrin. These cyclic flow
reductions (CFRs) that lead to experimental myocardial
ischemia, and potentially lethal arrhythmias, were shown to
be prevented by aspirin but not by heparin (9). This cyclic
flow model has been described as representing some of the
events occurring in a patient with unstable angina and useful
for studying mechanisms of unstable angina (10–12). The
model allows a reproducible pattern of recurrent thrombosis
to be established that then permits testing of potential
antithrombotic agents (11–15). A key feature of the model
is the provision of an internal control for each animal
(11–14). The model also permits potential antiplatelet
agents to be given intravenously or orally (13). Finally, the
model also allows for studies in anesthetized or awake,
unsedated animals (12,14,15). Although widely used and
quoted, this animal model, however, does not mimic very
well some of the conditions existing in patients with
atherosclerotic narrowing of coronary or peripheral arteries.
The model does not have many of the substrates found in
ruptured atherosclerotic plaques, especially the very throm-
bogenic lipid core (16). In addition, risk factors, such as
smoking, diabetes, hyperlipidemia or hypertension, associ-
ated with increased platelet activity and vascular disease, are
not usually associated with this model (17).
There are not, however, many alternative models that
permit repetitive experimental measurements of in vivo
platelet activity or platelet interactions with arterial walls
over time. Evaluation of ex vivo platelet “function” or level
of activity is labor intensive, difficult and usually can be done
at only one point in time (18,19). Other animal models (11)
or ex vivo perfusion chambers (20) offer some very distinct
advantages but possess unique disadvantages as well, which
are beyond the scope of this review. The authors are most
familiar with the use of the cyclic flow model, which has
recently been reviewed (11,21,22).
Cyclic flow reductions were first observed in 1978 in the
popliteal artery of patients with peripheral vascular disease
having intermittent claudication (23). In addition, cyclic
flow variations have now been observed in patients at the
time of angioplasty (24,25). Finally, the frequency and
severity of cyclic flow alterations and platelet aggregation
predicted the severity of neointimal proliferation after ex-
perimental stenosis and endothelial injury in conscious dogs
(15). The cyclic flow variations in both anesthetized and
conscious dogs and humans have been compared with the
clinical manifestations of unstable angina and their sequelae
by a number of authors (10,13,15,26). Seven antiplatelet
drugs, including aspirin, have been evaluated in the cyclic
flow model in several animal species, and were found to be
effective in vivo as platelet inhibitors (22). These drugs have
also been used in clinical trials with encouraging results (22).
Two drugs, dipyridamole and prostacyclin, failed to be
effective at clinical doses with acceptable hemodynamics in
the cyclic flow model, and also were shown to not be
effective platelet inhibitors in a variety of clinical trials
(22,27).
MECHANISMS OF PLATELET
ACTIVATION AND AGGREGATION: INPUT STIMULI
Platelet activation in vivo leading to platelet-mediated
coronary thrombosis can be considered to occur in several
linked phases (Fig. 1) (17,22). First, platelets adhere to a site
of vascular intimal injury where the antithrombotic proper-
ties of dysfunctional endothelium are lost. Subsequently,
many input stimuli can activate platelets in vivo and ulti-
mately cause adhesion, clumping, aggregation and thrombus
formation. These input stimuli or agonists can act indepen-
dently, and yet some are also synergistic with one another.
The net effects of these input stimuli are to raise platelet
cytosolic calcium, which triggers contraction of platelet
actin and myosin fibrils, leading to platelet shape change,
and the release reaction. This is the calcium mobilization
phase shown in the center of Figure 1. The final phase is the
activation and exposure of the membrane glycoprotein
IIb–IIIa fibrinogen receptor, shown on the right of Figure 1.
Many studies have been done that address ways to block the
various input stimuli and thereby decrease platelet activity.
Abbreviations and Acronyms
ADP 5 adenosine diphosphate
AMP 5 adenosine monophosphate
CFRs 5 cyclic flow reductions
C7E3 5 chimeric monoclonal antibody to the platelet
GPIIb-IIIa receptor
EDRF 5 endothelial-derived relaxing factor
GMP 5 guanosine monophosphate
NO 5 nitric oxide
PDE 5 phosphodiesterase
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CFRs in the canine model with coronary artery constric-
tion and intimal injury, and in patients with periodic
coronary thrombosis causing unstable angina, are caused by
a variety of different mediators or input stimuli singly and in
combination, besides thromboxane A2, which include sero-
tonin, thrombin, ADP, epinephrine, platelet-activating fac-
tor, oxygen-derived free radicals as well as shear stress,
shown on the left of Figure 1 (22,28–32). In this review, we
will attempt to compare effective experimental platelet
inhibitors in the CFR model with clinical trials of the same
platelet inhibitors.
ASPIRIN AS A PLATELET INHIBITOR
There has been considerable interest and success with the
use of aspirin to prevent platelet-mediated thrombotic
events in stenosed coronary and cerebral arteries.
The Antiplatelet Trialists’ meta-analysis showed a 25%
reduction in the incidence of cardiovascular events with the
use of aspirin (33). The Physicians’ Health Study showed a
44% reduction in the first incidence of myocardial infarction
(34). Identification of those patients and those types of
events likely to benefit from aspirin treatment and those not
likely to do so may serve as a means to detect those patients
who may be at greater risk in a clinical trial. For example,
the morning increase in myocardial infarction and stroke is
accompanied by a catecholamine surge in many but not all
patients, producing increased platelet activity (17,35,36).
The Physicians’ Health Study demonstrated a 59% reduc-
tion in morning myocardial infarctions in patients treated
with aspirin compared with controls, which is encouraging,
although a relatively small number of patients were in this
subgroup (37). A similar, although not comparable study,
was done with British doctors receiving daily aspirin (500
mg/d), which did not show a significant decrease in a first
myocardial infarction (38).
Recently, the benefits of aspirin for primary and second-
ary prevention of occlusive vascular disease were extensively
reviewed (39,40). There is a clear indication for the use of
aspirin to reduce the risk of death from cardiovascular causes
or nonfatal myocardial infarction and stroke in patients with
unstable angina or a history of myocardial infarction, tran-
sient cerebral ischemia or stroke (39,40).
These clear benefits of aspirin therapy described in
clinical trials of patients with atherothrombotic disease are
significant. However, the animal model suggests that there
may be some potential problems with aspirin and other
platelet inhibitors that should be assessed in clinical trials.
Therefore, we will examine some of these problems, com-
pare them with clinical trials and speculate on why some
investigators feel that aspirin is not a very potent platelet
inhibitor (17,41).
INPUT STIMULI OR AGONISTS THAT
INCREASE IN VIVO PLATELET ACTIVITY
BUT ARE ONLY PARTIALLY BLOCKED BY ASPIRIN
It has been shown in the animal model that the antithrom-
botic effect of aspirin can be overcome and periodic platelet
thrombus formation restored by the experimental infusion
of epinephrine (42), or by ventilating the animals with
cigarette smoke, producing free radicals and acute elevations
in endogenous catecholamines (43). In another study the
antithrombotic effects of aspirin and the prothrombotic
Figure 1. Schematic diagram showing the different input stimuli
on the left that can activate platelets in vivo. These stimuli act by
signal transduction through receptors to ultimately increase the
free cytosolic Ca21 level in platelets. In the center are the calcium
mobilization reactions that interact with the receptors and regulate
cytosolic free Ca21 ([Ca21]i). Adenosine triphosphate (ATP) is
converted to cyclic adenosine monophosphate (cAMP) by the
enzyme adenylate cyclase (AC). cAMP is broken down to AMP by
the enzyme phosphodiesterase. When cAMP is elevated, for
example by prostacyclin (PGI2) binding to a specific receptor and
stimulating adenylate cyclase (AC), some Ca21 is stored in the
dense tubules. This reduces cytosolic free Ca21 and decreases the
level of platelet activation. Another regulator of free cytosolic Ca21
is cyclic GMP. Guanosine triphosphate (GTP) is converted to
cGMP by guanylate cyclase (GC). cGMP is broken down by a
phosphodiesterase to produce GMP. When cGMP is elevated by
stimulation of GC by NO, free cytosolic Ca21 is reduced by two
mechanisms. Ca21 is inhibited from entering the platelet from the
plasma, and also Ca21 is inhibited from leaving the dense tubules.
This also reduces the available level of cytosolic Ca21. Thus
modulating free cytosolic Ca21 can increase or decrease platelet
activity. The final step in platelet-mediated thrombosis is the
exposure/activation of the platelet glycoprotein IIb-IIIa fibrinogen
receptor, which binds to fibrinogen to create a platelet aggregate.
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effects of epinephrine were compared simultaneously by
using the cyclic flow model and an ex vivo shunt through a
perfusion chamber in the same dogs. The perfusion cham-
ber had human fibrillar collagen as the thrombogenic
surface (44). The CFRs and ex vivo thrombosis in the
chamber were significantly inhibited by 10 mg/kg of aspirin
given intravenously. However, when epinephrine 10 mg/
min was infused intravenously for 5 min, both the CFRs
were restored in the stenosed arterial lumen and a significant
increase in thrombus formation occurred in the perfusion
chamber (44). Platelet activation produced in vivo by many
of the input stimuli, including thrombin, shown in Figure 1,
is enhanced by a synergistic effect with elevations of circu-
lating catecholamines (45). Catecholamine-enhanced
thrombogenesis and catecholamine-dependent vasocon-
striction may be important in humans because they may be
the link between emotional stress such as anger, circadian
variation of activity and heavy physical exercise and the
onset of acute cardiovascular disease (46). Hypercat-
echolaminergic states, which enhance thrombosis and vaso-
constriction, may trigger an acute coronary syndrome if they
coincide with, or help to cause, the rupture of an athero-
sclerotic plaque (17,46). Thus, the animal model would
suggest that we should look at the levels of catecholamines
in this subset of patients to see how well any platelet
inhibitor protects against acute thrombosis when cat-
echolamines are elevated.
The animal model also demonstrates that high shear
forces acting on platelets passing through severely narrowed
stenoses can also overcome the inhibitory effects of aspirin
(47,48). Furthermore, direct shear stress-induced platelet
aggregation is not significantly inhibited by aspirin
(17,47,48). Finally, it has been shown recently that epineph-
rine acts synergistically with shear stress to induce platelet
aggregation, and that this synergistic interaction is likewise
unaffected by aspirin (49).
CLINICALLY HYPERACTIVE PLATELETS
Some patients with coronary artery disease have more active
platelets than healthy control subjects. Patients with diabe-
tes mellitus type I and type II, hypercholesterolemia and
some forms of hypertension have increased platelet aggre-
gability (17). In one study the hyperactive platelets of
insulin-dependent diabetics were inhibited less by aspirin
than the platelets of nondiabetics (50). In addition, studies
on the blood of patients who had an atherothrombotic
stroke within the previous 72 h show they have hyperreac-
tive platelets that are more susceptible to shear-induced
aggregation. This hyperactivity was not significantly de-
creased by aspirin treatment (51). There are some patients
who are resistant to the effects of aspirin and whose platelets
are not inhibited significantly by aspirin. In another study of
180 post-stroke patients, 120 showed a good platelet inhib-
itory response 12 h after 500 mg of aspirin postoperatively
(aspirin responders) (52). However, 60 patients did not
show a significant platelet inhibitory response 12 h after
500 mg of aspirin PO (secondary aspirin nonresponders).
After a 24-month follow-up, where all patients received 3 3
500 mg of aspirin per day, a second fatal or nonfatal stroke
or myocardial infarction occurred in 4.4% of the aspirin
responders, but these events occurred in 40% of the aspirin
nonresponders (p , 0.001) (52). Thus, there appear to be at
least some individuals identified whose platelets may not be
significantly inhibited by daily aspirin therapy, and they go
on to have an increased incidence of ischemic vascular
events (52). These small but controlled studies should give
us insight and clues as to what to look for when planning
and interpreting future trials, and also interpreting results
obtained with the animal model. The potential clinical
importance of these observations was recently demonstrated
by Eichhorn et al. in patients with unstable angina under-
going coronary angioplasty (24). CFRs measured with an
intravascular doppler flowmeter and thought to be platelet
mediated were documented in these patients despite aspirin
and heparin treatment (24). The occurrence of CFRs in
these aspirin-treated patients may have resulted from the
combination of elevated catecholamines and turbulence in
the rough, stenosed lumen producing turbulent flow, which
increased shear forces acting on the platelets during the
procedure, or they may have been aspirin resistant (52). In
addition, the ruptured atherosclerotic plaque leading to
unstable angina also exposes materials that may provoke
thrombosis by mechanisms that aspirin does not block, such
as tissue factor (17). Plasma epinephrine levels measured in
patients during coronary angiography procedures range
from 100 to 300 pg/ml compared with 50 to 75 pg/ml in
healthy controls (unpublished observations, J.D.F.). This
increase in plasma concentration is enough to overcome the
inhibitory effects of aspirin in vivo and in vitro (42). In a
more recent study, CFRs were also observed in patients
treated with aspirin and heparin at the time of angioplasty.
The CFRs were subsequently abolished with an antibody
that blocks the platelet GPIIb-IIIa receptor (25). This is a
much more potent platelet inhibitor than aspirin (see
below).
Patients with atherosclerotic narrowing of arteries and
subsequent plaque rupture may be in a worse situation than
the animal cyclic flow model used to study platelet interac-
tions with damaged arterial walls. In the presence of
experimental acute deep arterial injury, similar to that
created by balloon angioplasty or rupture of an atheroscle-
rotic plaque, aspirin reduces thrombus formation by only
55% (53). Exposure of tissue factor deep in the arterial wall
will stimulate thrombosis, and this effect is not inhibited by
aspirin (17). In addition, fresh mural thrombus is a very
potent stimulus for further growth of thrombus in spite of
aspirin therapy (17,54). Thrombin is also a major factor in
fresh mural thrombus, and aspirin does not block thrombin
activation of platelets to any significant degree (17,55,56).
The cyclic flow model demonstrated some inhibition of
platelet activation by heparin (30). However, the mecha-
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nism by which heparin inhibits thrombin production is not
very effective within the thrombus itself, where the heparin-
antithrombin III complex is excluded. There is recent
interest in the use of more thrombin-specific inhibitors such
as hirudin or hirulog (54). These agents are much more
effective at inhibiting the growth of new thrombus on fresh
mural thrombus than aspirin (54).
ADP RECEPTOR BLOCKADE
Ticlopidine and its analog, clopidogrel, are thienopyridine
derivatives that exert their antiplatelet action by inhibiting
adenosine phosphase (ADP) binding to its platelet recep-
tors, thereby blocking ADP-induced platelet aggregation
(41). These agents may also partially inhibit platelet re-
sponse to other stimuli, which act in part by causing the
release of ADP from endogenous platelet granule pools.
Based on large randomized trials, ticlopidine was found
to be at least as effective as aspirin for the prevention of
subsequent vascular attacks and death in patients with
transient ischemic attacks, completed atherothrombotic
strokes, unstable angina and intermittent claudication
(57,58). Since ticlopidine inhibits primarily ADP-induced
platelet aggregation, it has been suggested that a lower dose
of ticlopidine, combined with aspirin to block thromboxane
production, might be more effective (58).
A new thienopyridine derivative, clopidogrel, is currently
being studied. The cyclic flow dog model demonstrated that
clopidogrel was very effective at inhibiting platelet activity
and abolishing cyclic flow reductions when given as an
intravenous infusion (32). A randomized blinded trial of
clopidogrel versus aspirin in patients at risk of ischemic
events, the CAPRIE trial, suggested that clopidogrel is
more effective than aspirin (59). This was the first study of
an antiplatelet drug to include patients from the clinical
subgroups of ischemic cerebrovascular, cardiac and periph-
eral arterial disease under a common protocol. Clopidogrel
has fewer side effects than ticlopidine and appears to be
more potent (59). This study suggests that the ADP input
stimuli may be more significant than the thromboxane A2
input stimuli to platelet activation. The pharmacology of
clopidogrel has recently been reviewed (60).
Given these multiple pathways or input stimuli for
platelet activation and the fact that aspirin primarily inhibits
only one pathway, it is interesting to note that aspirin
provides as much protection against acute atherothrombotic
events as has been demonstrated in numerous clinical trials
(17,39,40).
PLATELET CYTOSOLIC CALCIUM MOBILIZATION
Regulation of cyclic AMP and cGMP. Many tissues,
including cardiac, skeletal and vascular smooth muscle, have
their level of activity regulated in part by the level of cyclic
nucleotides, ie, cyclic adenosine monophosphate (AMP)
and cyclic guanosine monophosphate (GMP). These cyclic
nucleotides regulate the level of cytosolic free [Ca21]i (22).
The many input stimuli that can potentially activate
platelets also act through this common mechanism, ie, to
increase the level of free cytosolic calcium in the platelet.
Thus, it would seem logical to attempt to decrease platelet
function by regulating the cytosolic ionized calcium concen-
tration ([Ca21]i), shown in the center of Figure 1. Two of
the primary mechanisms for regulating platelet cytosolic
calcium are the levels of cyclic AMP and cyclic GMP.
These two general endogenous systems are potential targets
for attenuation of platelet activation by sequestering cyto-
solic calcium. Prostacyclin and its analogues increase cyclic
AMP, while endothelial-derived relaxing factor (EDRF)
and nitric oxide (NO) analogues increase cyclic GMP. In
either case, by increasing cyclic AMP or cyclic GMP,
cytosolic Ca21 flux and platelet activation are reduced (61).
In Figure 1, the input stimuli acting through specific
receptors all have the same basic effect on platelets, which is
to raise cytosolic calcium.
NO DONORS TO RAISE CYCLIC GMP
Organic nitrates are modest inhibitors of in vitro platelet
aggregation (62). We have shown in the cyclic flow model
that intravenous nitrates or NO donors, such as nitroglyc-
erin, (63) and to a greater extent the direct NO donors,
sodium nitroprusside (64) or the direct NO donor, NO gas
and S-NO-cysteine (65), can effectively inhibit platelet
activity in vivo at clinically relevant doses and prevent
experimental coronary artery thrombosis. They do this, at
least in part, by elevating platelet cGMP (64,65). In
addition, these NO donors protect against renewal of
thrombus formation and CFRs in the cyclic flow model by
elevated plasma epinephrine, which aspirin does not
(64,65). Studies in healthy subjects and patients with stable
angina pectoris have shown that transdermal glyceryl trini-
trate and sublingual nitroglycerin (both NO donors) can
inhibit platelet activity ex vivo (66–68). This was shown
both by ex vivo whole blood aggregation studies and by
drawing patient blood through a perfusion chamber. The
patient blood was exposed to porcine aortic media in the
chamber at high shear comparable with that created by
coronary artery stenosis (67). The platelet aggregation
studies showed significant inhibition by nitrates to both
collagen and ADP agonists. Aspirin does not completely
inhibit ADP or collagen-induced aggregation, but NO does
(69). Aspirin also does not effectively inhibit platelet depo-
sition on damaged arterial walls in perfusion chambers (44).
Thus, both the cyclic flow model, patient ex vivo platelet
aggregation studies and drawing NO-treated human blood
over exposed porcine media all showed inhibition of platelet
activity by the NO donor.
It has been speculated that some of the beneficial clinical
effects of organic nitrates in unstable angina and the onset of
myocardial infarction are due to their platelet inhibiting
properties (70–72). It is known that during an evolving
myocardial infarction (MI), the patient’s plasma cat-
299JACC Vol. 33, No. 2, 1999 Folts et al.
February 1999:295–303 Aspirin as an Antithrombotic Agent
echolamines are elevated. Studies with the animal model
would suggest that an NO donor may be of more benefit in
this particular situation than aspirin, but this will require a
well-designed study to clearly demonstrate this.
In two large clinical trials, ISSIS-4 and GISSI-3, there
was no major overall reduction in mortality when glyceryl
trinitrate was given for 6 weeks after an acute MI (73,74).
This may be due to starting the nitrate too late, ie, 6 weeks
after the acute MI, and because nitrates are not as potent as
direct NO donors (70).
It may be that the use of better NO donors than nitrates,
studied at a time when platelet-vessel wall interaction is
more intense, such as during angioplasty or unstable angina,
may make it easier to detect the platelet inhibitory effects of
NO.
For example, in seven control patients, coronary angio-
plasty, which produces deep arterial injury, caused an
increase in platelet activation as demonstrated by a rise in
platelet surface expression of P-selectin and the platelet
fibrinogen receptor, the integrin GPIIb-IIIa, 5–10 min after
the balloon dilation. This occurred in spite of treatment
with aspirin, nitroglycerin and heparin. In six patients, the
intracoronary infusion of S-nitrosoglutathione, a much
better NO donor than nitroglycerin, started 10 min before
angioplasty, significantly inhibited this percutaneous trans-
luminal coronary angioplasty–induced increase in platelet
surface expression of P-selectin and the platelet integrin
GPIIb-IIIa (75). Thus, the animal model and a group of
small preliminary patient studies suggest the NO donors
may significantly reduce in vivo thrombosis by elevating
platelet cyclic GMP levels. The NO donors raise platelet
cyclic GMP levels, which lowers [Ca21]i levels. This is a
biochemical step occurring after the input stimuli, and the
animal model studies suggest that NO is likely to prevent
renewal of platelet activity by elevated catecholamine levels
(Fig. 1). Well-planned clinical trials should help to deter-
mine if NO donors can inhibit platelet activity better than
aspirin and whether this has clinical relevance.
CALCIUM CHANNEL BLOCKERS
Since many platelet functions are dependent on the level of
intracellular calcium for optimal activation, calcium channel
blockers were tested in the animal model. Early in vitro and
ex vivo studies of the effects of calcium channel blockers
showed some inhibition of platelet aggregation but required
higher doses than can be achieved in vivo.
We tested the acute effect of several calcium channel
blockers, including verapamil (0.4 mg/kg), in the cyclic flow
model at doses comparable with those given intravenously
clinically, and found they did not significantly decrease in
vivo platelet activity (76). We did observe, however, that
this low dose of verapamil was synergistic with aspirin,
abolished acute thrombus formation and protected against
renewal of platelet thrombus formation with elevated
plasma epinephrine levels (76). A clinical study using a
higher dose of slow release verapamil (240 mg/d) given for
7 d did show that this higher dose of verapamil significantly
decreased thrombus formation when patient blood was
drawn over damaged porcine aortic media at shear forces
typical of an arterial stenosis (77). The verapamil also
decreased thrombin induced ex vivo platelet aggregation. In
this study, the higher dose of verapamil was quite effective
by itself, and there was no evident synergism when aspirin
(325 mg/day) was added to the verapamil treatment.
Another group of calcium channel blockers, called dihy-
dropyridines, have been developed. The calcium channel
blocker, amlodipine, a newer dihydropyridine, was studied
in the cyclic flow animal model, and it was found that
0.4 mg/kg IV did significantly inhibit platelet function. This
dose was also synergistic with aspirin (78). The amlodipine
alone provided significant protection against the renewal of
platelet activity by elevated plasma epinephrine levels, while
the addition of 5 mg/kg of aspirin gave complete protection
(78). A large overview of trials with calcium channel
blockers in acute myocardial infarction and unstable angina
published in 1989 showed no apparent reduction in the risk
of initial or recurrent infarction or death (79). However, the
calcium channel blockers are a very diverse group of com-
pounds and have been prescribed in a range of doses, along
with other medications. Thus, it may be that more discrete
studies with clearer endpoints are needed, to show if newer
calcium channel blockers, like amlodipine, can inhibit acute
thrombotic events.
PHOSPHODIESTERASE INHIBITORS
Another approach to reduce platelet cytosolic calcium is by
raising cyclic AMP with the use of a phosphodiesterase
(PDE) inhibitor, shown in the center of Figure 1. Dipyr-
idamole was thought to inhibit platelet activity in part
because it is a PDE inhibitor, but it appears to be more
effective on vascular smooth muscle PDEs than platelet
PDEs (80). Dipyridamole was totally ineffective at inhibit-
ing platelet activity and acute thrombus formation in the
cyclic flow model, added nothing to the effects of aspirin
(81) and was of very limited value in most clinical trials (27).
FINAL COMMON PATHWAY:
PLATELET GPIIB/IIIA
INTERACTION WITH FIBRINOGEN
The final step in platelet activation, regardless of the type of
input stimuli involved, is the exposure and activation of the
platelet fibrinogen receptor, the integrin GPIIb-IIIa (Fig.
1). In the cyclic flow animal model of unstable angina, a
monoclonal antibody (7E3), now called abciximab or Reo-
Pro™, to this receptor was a very potent platelet inhibitor
and completely protected against periodic acute platelet-
mediated thrombus formation and CFRs. The CFRs were
not renewed with elevations in plasma epinephrine com-
bined with severe increases in the amount of stenosis and
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shear forces (82). However, there was prolongation of the
template bleeding time. Dr. Willerson’s group showed that
some patients with acute unstable angina at the time of
angioplasty, treated with aspirin, still had CFRs measured
with a Doppler catheter (24). In another patient group with
unstable angina, these authors showed that in those patients
who had CFRs in spite of aspirin treatment, the infusion of
the 7E3 antibody abolished the CFRs (25). A chimeric
version (C7E3) of this antibody was produced to decrease
the potential antigenicity. Adding this agent to aspirin and
heparin produced a significant decrease in the acute throm-
botic complications of coronary artery angioplasty compared
with aspirin and heparin alone (83), and the benefits
persisted for at least 6 months (84). In addition, C7E3
added to aspirin and heparin therapy significantly reduced
thrombotic complications and myocardial infarction during
angioplasty in patients with refractory unstable angina (85).
Angioplasty produces deep arterial injury exposing tissue
factor and the thrombogenic materials beneath the fibrous
cap overlying atherosclerotic lesions. Thus, it is not surpris-
ing that C7E3 combined with aspirin and heparin was
much more potent that aspirin and heparin alone.
As suggested in Figure 1, blocking the glycoprotein
IIb-IIIa fibrinogen receptor, ie, the final common pathway,
is likely to be the most potent way to inhibit platelet activity
in vivo. However, with this great potency comes increased
risk of bleeding. A group of glycoprotein IIb-IIIa receptor
inhibitors is now available for both parental and oral use.
Many of these are being used in clinical trials and they also
appear to be much more effective than aspirin for unstable
angina and coronary angioplasty. These data have recently
been extensively reviewed (86,87).
SUMMARY
It would appear that with the exception of more specific
thrombin inhibitors, and possibly blockers of the ADP
receptor, there is little advantage in attempting to individ-
ually block the many input stimuli that activate platelets as
a means to inhibit platelet activity and provide a better
antithrombotic effect. Consideration of the primary phases
of platelet activation and the place where a platelet inhibitor
acts, as illustrated in Figure 1, may facilitate an understand-
ing of the efficacy and potency of platelet-inhibiting drugs as
they become available. Aspirin will continue to be widely
used for patients with vascular disease (5,6); however, there
are a number of situations in which increased thrombotic
risk requires the use of a more potent platelet inhibitor than
aspirin. Conditions such as unstable angina, angioplasty,
coronary stenting and thrombolysis are likely to require
more potent platelet inhibitors. In these acute clinical
situations, the fibrous cap over an atherosclerotic plaque has
been ruptured or may be ruptured by interventional proce-
dures. This produces deep arterial injury and exposes a
much more thrombogenic surface.
The use of more potent NO donors may offer an
alternative means of reducing platelet activity by elevating
platelet cyclic GMP levels and lowering platelet cytosolic
calcium. An attractive feature of this form of intravenous
therapy is that platelet function will return to normal when
the use of the NO donor is terminated. In those instances
when a very potent platelet inhibitor is needed, the glyco-
protein IIb-IIIa fibrinogen receptor antagonists can be
utilized. As oral forms of GPIIb-IIIa receptor antagonists
become available, they may be useful for reducing the
problems of restenosis and intimal hyperplasia that occur
after angioplasty, atherectomy and arterial stenting, which
are thought to be due in part to significantly increased
platelet interactions with severely damaged arterial walls,
and for which aspirin has not been very effective.
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